- Home
- CEP vs ELTX Comparison
CEP vs ELTX Comparison
Compare CEP & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- ELTX
- Stock Information
- Founded
- CEP 2020
- ELTX 2011
- Country
- CEP United States
- ELTX United States
- Employees
- CEP N/A
- ELTX N/A
- Industry
- CEP
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- CEP
- ELTX Health Care
- Exchange
- CEP NYSE
- ELTX Nasdaq
- Market Cap
- CEP 131.6M
- ELTX 121.7M
- IPO Year
- CEP 2024
- ELTX N/A
- Fundamental
- Price
- CEP $31.51
- ELTX $5.40
- Analyst Decision
- CEP
- ELTX Strong Buy
- Analyst Count
- CEP 0
- ELTX 2
- Target Price
- CEP N/A
- ELTX $9.50
- AVG Volume (30 Days)
- CEP 8.6M
- ELTX 35.2K
- Earning Date
- CEP 01-01-0001
- ELTX 05-19-2025
- Dividend Yield
- CEP N/A
- ELTX N/A
- EPS Growth
- CEP N/A
- ELTX N/A
- EPS
- CEP 0.24
- ELTX N/A
- Revenue
- CEP N/A
- ELTX N/A
- Revenue This Year
- CEP N/A
- ELTX N/A
- Revenue Next Year
- CEP N/A
- ELTX N/A
- P/E Ratio
- CEP $142.97
- ELTX N/A
- Revenue Growth
- CEP N/A
- ELTX N/A
- 52 Week Low
- CEP $9.99
- ELTX $3.34
- 52 Week High
- CEP $59.75
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- ELTX 48.43
- Support Level
- CEP N/A
- ELTX $4.85
- Resistance Level
- CEP N/A
- ELTX $5.94
- Average True Range (ATR)
- CEP 0.00
- ELTX 0.50
- MACD
- CEP 0.00
- ELTX 0.14
- Stochastic Oscillator
- CEP 0.00
- ELTX 56.45
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.